{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:55:49Z","timestamp":1773410149349,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100031723","name":"Amgen GmBH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03248-x","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:46:55Z","timestamp":1750477615000},"page":"4023-4047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-3109","authenticated-orcid":false,"given":"H. Tilman","family":"Steinmetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Ertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tram","family":"Nham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Flossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"3248_CR1","unstructured":"Erdmann F, Spix C, Katalinic A, et al. Robert Koch Institut. Krebs in Deutschland f\u00fcr 2017\/2018. 2021. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2021\/krebs_in_deutschland_2021.pdf?__blob=publicationFile. Accessed 13 Nov 2024."},{"issue":"6","key":"3248_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","volume":"29","author":"MR LeBlanc","year":"2020","unstructured":"LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review. Qual Life Res. 2020;29(6):1419\u201331. https:\/\/doi.org\/10.1007\/s11136-019-02392-6.","journal-title":"Qual Life Res"},{"issue":"5","key":"3248_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00520-014-2552-1","volume":"23","author":"K Colson","year":"2015","unstructured":"Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer. 2015;23(5):1431\u201345. https:\/\/doi.org\/10.1007\/s00520-014-2552-1.","journal-title":"Support Care Cancer"},{"issue":"7","key":"3248_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542\u201360. https:\/\/doi.org\/10.1038\/s41375-018-0040-1.","journal-title":"Leukemia"},{"issue":"2","key":"3248_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2): e528. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Hemasphere"},{"issue":"8","key":"3248_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107. https:\/\/doi.org\/10.1002\/ajh.26590.","journal-title":"Am J Hematol"},{"issue":"12","key":"3248_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1159\/000519419","volume":"44","author":"T Steinmetz","year":"2021","unstructured":"Steinmetz T, Ernst A, Hellmich M, Heinz M, Totzke U. Effectiveness of long-term treatment of multiple myeloma in regular care: comparison of a longitudinal and a cross-sectional analysis approach. Oncol Res Treat. 2021;44(12):662\u201371. https:\/\/doi.org\/10.1159\/000519419.","journal-title":"Oncol Res Treat"},{"issue":"3","key":"3248_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12325-021-02022-z","volume":"39","author":"HT Steinmetz","year":"2022","unstructured":"Steinmetz HT, Singh M, Milce J, et al. Management of patients with relapsed and\/or refractory multiple myeloma treated with novel combination therapies in routine clinical practice in Germany. Adv Ther. 2022;39(3):1247\u201366. https:\/\/doi.org\/10.1007\/s12325-021-02022-z.","journal-title":"Adv Ther"},{"issue":"6","key":"3248_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.25764","volume":"95","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: implications for survivorship. Am J Hematol. 2020;95(6):672\u201390. https:\/\/doi.org\/10.1002\/ajh.25764.","journal-title":"Am J Hematol"},{"key":"3248_CR10","unstructured":"Kort\u00fcm M, Auner HW, Bassermann F, et al. Onkopedia: multiple myeloma. 2024. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiples-myelom\/@@guideline\/html\/index.html. Accessed Oct 2024."},{"issue":"26","key":"3248_CR11","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3248_CR12","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","volume":"18","author":"M Mohty","year":"2018","unstructured":"Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319. https:\/\/doi.org\/10.1016\/j.clml.2018.06.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"3248_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ejh.13835","volume":"109","author":"I Spicka","year":"2022","unstructured":"Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022;109(5):504\u201312.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3248_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/bjh.18233","volume":"198","author":"O Landgren","year":"2022","unstructured":"Landgren O, Weisel K, Rosinol L, et al. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022;198(6):988\u201393.","journal-title":"Br J Haematol"},{"issue":"1","key":"3248_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Brit J Haematol. 2016;175(1):66\u201376. https:\/\/doi.org\/10.1111\/bjh.14193.","journal-title":"Brit J Haematol"},{"issue":"2","key":"3248_CR16","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160\u201375. https:\/\/doi.org\/10.1016\/j.clml.2020.10.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"3248_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ejh.14161","volume":"112","author":"M Lehne","year":"2024","unstructured":"Lehne M, Kort\u00fcm KM, Ramasamy K, et al. Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain. Euro J Haematol. 2024;112(5):701\u201313. https:\/\/doi.org\/10.1111\/ejh.14161.","journal-title":"Euro J Haematol"},{"issue":"Supplement 1","key":"3248_CR18","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1182\/blood-2022-163074","volume":"140","author":"N Puig","year":"2022","unstructured":"Puig N, Hungria V, Chari A, et al. Global treatment standard in multiple myeloma remains elusive: updated results from the INSIGHT MM global, prospective, observational study. Blood. 2022;140(Supplement 1):4269\u201372. https:\/\/doi.org\/10.1182\/blood-2022-163074.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3248_CR19","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2019-122706","volume":"134","author":"M Merz","year":"2019","unstructured":"Merz M, Broek IV, P\u00e9rez M, et al. Evolving treatment trends in relapsed\/refractory multiple myeloma (RRMM) in Europe from 2016 to 2018: analysis of a multi-national survey. Blood. 2019;134(Supplement 1):3115. https:\/\/doi.org\/10.1182\/blood-2019-122706.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3248_CR20","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1016\/j.clml.2018.07.146","volume":"18","author":"C Costello","year":"2018","unstructured":"Costello C, Boccadoro M, Usmani SZ, et al. A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study. Clin Lymphoma Myeloma Leuk. 2018;18(Supplement 1):S247\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3248_CR21","unstructured":"Mai C, Ertl S, Schneider E, Leberre M, Yilmaz M, Raffe A. Key drivers for treatment choice in lenalidomide-exposed and refractory multiple myeloma patients in the real world. Analysis conducted in the EU5 countries and the US. Presented at the American Society of Hematology (ASH); 7\u201310 December 2024. San Diego, CA. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper206913.html. Accessed 2 Dec 2024."},{"issue":"5","key":"3248_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16764","volume":"191","author":"D Kazandjian","year":"2020","unstructured":"Kazandjian D, Mo CC, Landgren O, Richardson PG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020;191(5):692\u2013703. https:\/\/doi.org\/10.1111\/bjh.16764.","journal-title":"Br J Haematol"},{"issue":"25","key":"3248_CR23","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2217\/fon-2022-0378","volume":"18","author":"L Batchelder","year":"2022","unstructured":"Batchelder L, Philpott S, Divino V, et al. Physician treatment preferences for relapsed\/refractory multiple myeloma: a discrete choice experiment. Future Oncol. 2022;18(25):2843\u201356. https:\/\/doi.org\/10.2217\/fon-2022-0378.","journal-title":"Future Oncol"},{"key":"3248_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.39.28_suppl.239","author":"L Batchelder","year":"2021","unstructured":"Batchelder L, Philpott S, Divino V, et al. Physician decision-making on use of treatments for relapsed\/refractory multiple myeloma (RRMM) in later lines: what drives preferences? J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2020.39.28_suppl.239.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3248_CR25","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/j.clml.2023.02.010","volume":"23","author":"UH Mellqvist","year":"2023","unstructured":"Mellqvist UH, Steinmetz HT, Perrot A, et al. Patient confidence and information preferences during the treatment decision-making process: results from a large multiple myeloma patient survey across 12 countries in Europe and Israel. Clin Lymphoma Myeloma Leuk. 2023;23(5):e240\u201351. https:\/\/doi.org\/10.1016\/j.clml.2023.02.010. (e12).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"3248_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/tbm\/ibac099","volume":"13","author":"CL Bylund","year":"2023","unstructured":"Bylund CL, Eggly S, LeBlanc TW, et al. Survey of patients and physicians on shared decision-making in treatment selection in relapsed\/refractory multiple myeloma. Transl Behav Med. 2023;13(4):255\u201367. https:\/\/doi.org\/10.1093\/tbm\/ibac099.","journal-title":"Transl Behav Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03248-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:24:44Z","timestamp":1757193884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3248"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03248-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. H. Tilman Steinmetz has received research funding from Accord Healthcare, Amgen, Celgene, Novartis, Vifor; he has membership on an entity\u2019s board of directors, speaker\u2019s bureau, or its advisory committees with AbbVie, Accord Healthcare, Alexion, Amgen, Ariad, Bluebird Bio, BMS\/Celgene, Boehringer, Gilead, Hexal\/Sandoz, Incyte, IoMedico, Janssen-Cilag, Lilly, Miltenyi, Novartis, Oncopeptides, Otsuka, Pfizer, Pharmacosmos, Sanofi, Shire, Sobi, Stemline, TAD, Takeda, Vifor; and has received travel grants from Alexion, Amgen, Bayer, BMS\/Celgene, Janssen-Cilag, Sanofi, Sobi, and Takeda. Katherine Houghton and Tram Nham are employees of RTI Health Solutions, which received funding from Amgen GmbH (Germany) to conduct this research study and to provide medical writing support. Beate Brinkmann, Dr. Franziska Ertel, and Dr. Carmen Flossmann are employees of Amgen GmbH (Germany) and hold Amgen stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted retrospectively from data obtained for clinical purposes and complied with all relevant market research guidelines and legal obligations. No identifiable protected health information was extracted during the study, and the authors consulted with the institutional review board (IRB) of Nordrhein (D\u00fcsseldorf), who determined that the present study did not need ethical approval owing to the anonymisation of the data collected. An official waiver of ethical approval was granted from the IRB of Nordrhein (D\u00fcsseldorf) on 31 May 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}